ZW 25

Drug Profile

ZW 25

Alternative Names: ZW25

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Ovarian cancer

Most Recent Events

  • 11 Sep 2017 Adverse event data from a phase I trial in Breast cancer, Gastric cancer, and Ovarian cancer released by Zymeworks
  • 04 Jun 2017 Efficacy and adverse events data from a phase I trial in Ovarian cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
  • 02 Jun 2017 Pharmacokinetic data from a phase I trial in Breast cancer and Gastric cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top